reports
Paramount Gold Expects to Receive Final Federal Approvals in January 2...
Paramount Gold Expects to Receive Final Federal Approvals in January 2026 for its High Grade Grassy Mountain Gold Project and Provides Corporate Update on 2025 Achievements WINNEMUCCA, Nev., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) announces today that the U.S. Bureau of Land Management (“BLM”) has confirmed that the final Environmental Impact Statement (“EIS”) and Record of Decision (“ROD”) for the Grassy Mountain Gold Project are scheduled to be issued in January 2026. Project and permitting timelines can be tracke...
G-III Apparel Group Ltd: 1 director
A director at G-III Apparel Group Ltd sold 93,609 shares at 30.740USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Paramount Gold Announces the Voting Results of Its 2025 Annual General...
Paramount Gold Announces the Voting Results of Its 2025 Annual General Meeting WINNEMUCCA, Nev., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (“Paramount” or the “Company”) (NYSE American: PZG) announces the results of the votes from its Annual General Meeting (“AGM”) of stockholders held on December 11, 2025. There were 78,338,726 shares outstanding and entitled to vote at the meeting as of the record date of October 16, 2025, of which, 46,146,357 shares or 58.91 % voted. The stockholders elected the following seven individuals to Paramount’s Board of Directors for a on...
G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results an...
G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results and Updates Fiscal 2026 Outlook; Initiates First Ever Quarterly Dividend Program Net Income Per Diluted Share of $1.84 and Non-GAAP Net Income Per Diluted Share of $1.90 for the Third Quarter, Both Exceeding GuidanceNet Sales of $988.6 Million for the Third QuarterRaises GAAP and Non-GAAP Net Income Per Diluted Share GuidanceMaintains Strong Cash and Availability PositionIntroduces First Ever Quarterly Dividend of $0.10 Per Share NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- G-III Apparel Group, Ltd. (NasdaqGS: GIII) (“G-I...
Paramount Gold Nevada Receives Draft Consolidated Permit Package From ...
Paramount Gold Nevada Receives Draft Consolidated Permit Package From the State of Oregon for the Grassy Mountain Gold Project WINNEMUCCA, Nev., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) announces today that The Oregon Department of Geology and Mineral Industries (“DOGAMI”) has published the draft consolidated permit package for the Grassy Mountain Gold Project on behalf of all state permitting and cooperating agencies. This represents the first time in Oregon’s history that a mining project has advanced through the ...
G-III Apparel Group Announces Date for Third Quarter Fiscal 2026 Resul...
G-III Apparel Group Announces Date for Third Quarter Fiscal 2026 Results NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- G-III Apparel Group, Ltd. (NASDAQ: GIII) today announced that it will release its third quarter fiscal 2026 earnings before the market opens on Tuesday, December 9, 2025. Management will host a conference call to discuss results at 8:30 a.m. ET that same day, followed by a question and answer session for the investment community. To participate via telephone, please register in advance at this link: . Upon registration, all telephone participants will receive a confirmatio...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Jonathan Moreland
UEC URANIUM ENERGY CORP
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
STAA STAAR SURGICAL CO.
OPK OPKO HEALTH INC.
LQDT LIQUIDITY SERVICES
LMAT LEMAITRE VASCULAR INC.
FAST FASTENAL COMPANY
BEN FRANKLIN RESOURCES INC.
SRTS SENSUS HEALTHCARE
RSSS RESEARCH SOLUTIONS
ULBI ULTRALIFE
EVLV EVOLV TECHNOLOGIES HLDGS INC
WEST WESTROCK COFFEE COMPANY LLC
SMRT SMARTRENT INC
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
SLS SELLAS LIFE SCIENCES GROUP INC
BATRK LIBERTY MEDIA CORP
ANNX ANNEXIN PHARMACEUTICALS AB (PUBL)
OESX ORION ENERGY SYSTEMS INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- David Nierengarten
- Dennis Pak
- Martin Fan
Xilio Therapeutics Announces Pipeline and Business Updates and Third Q...
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and ...
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobar...
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting 40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTH...
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immun...
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile Phase 2 data for vilasto...
- Wedbush Research
RNG RINGCENTRAL INC. CLASS A
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
ROKU ROKU INC. CLASS A
DDOG DATADOG INC CLASS A
FUBO FUBOTV
PLTR PALANTIR TECHNOLOGIES
NUVB NUVATION BIO INC (A)
TTD THE TRADE DESK
PAY INC.
SLDB PAYMENTUS HLDGS INC
SOLID BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Martin Fan
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Ru...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective November 1, 2025, the company granted a non-qualified stock option to purchase 5,700 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.7967 p...
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Thomas Yip
- Yun Zhong
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
OCUP OCUPHIRE PHARMA INC
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
HOWL INC
GMTX WEREWOLF THERAPEUTICS INC
SGMT GEMINI THERAPEUTICS INC
RNAC SAGIMET BIOSCIENCES INC
MAZE CARTESIAN THERAPEUTICS INC
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlightin...
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will present a late-breaking poster presentation for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, at the Society for ...
- Jonathan Moreland
ASA ASA
NSC NORFOLK SOUTHERN CORPORATION
RVP RETRACTABLE TECHNOLOGIES INC.
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
NWFL NORWOOD FINANCIAL CORP.
BWB BRIDGEWATER BANCSHARES
RYES PATRIOT MINEFINDERS INC.
BHRB BURKE & HERBERT BANK & TR/VA
EBC EASTERN BANKSHARES INC
VANI VIVANI MEDICAL INC
GF THE NEW GERMANY FUND
INC.
- David Nierengarten
- Dennis Pak
- Martin Fan
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.